Company · Private
Rgenta Therapeutics, Inc.
Key figures
- SEC number
- 1801266
Source: SEC EDGAR filings and company facts; checked 4 Nov 2026
About
Rgenta Therapeutics is a clinical-stage biotechnology company developing oral small molecule medicines that target RNA, with a focus on cancer and neurological disorders.
Rounds and raises
3 Nov 2026
Form D: $42M sold of $130M offered, Other Technology SEC
Source: SEC EDGAR Form D and the linked articles. All raises this week
Questions and answers
- What does Rgenta Therapeutics, Inc. do?
- Rgenta Therapeutics is a clinical-stage biotechnology company developing oral small molecule medicines that target RNA, with a focus on cancer and neurological disorders.
Free, with no account
The rest of this page is free to read: 12 quarters of figures, every filing and document, earnings call transcripts, holders and ownership changes, the Brain's cards and graph, exports to Excel.
Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.